COO The Cooper Companies, Inc.

내부자 3명 장내 매수. 다만 애널리스트 전망 하향 우세.

종가$58.97
시가총액$110억
업종헬스케어
PER19.3배
매출 성장(최근 4분기)+4.7%
영업이익률13%
애널리스트 순상향률-94%
목표가 상승여력+12%
공매도 거래 비중29%
1년 수익률-21%

The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical, toric, and multifocal contact lenses that address vision challenges, such as astigmatism, presbyopia, and myopia. Its CooperSurgical segment focuses on family and women's health care, which provides fertility products and services, medical devices, and contraception, as well as cryostorage, such as cord blood and cord tissue storage. This segment offers Paragard, a

2026-10-21 기준 · 출처: SEC EDGAR, FINRA, yfinance · 정보 제공용이며 투자 권유가 아닙니다

같은 업종 종목